Grifols

Catalan pharmaceutical company

GRF BME Madrid · home listing GRFS Nasdaq ISIN ES0171996012 LEI 959800HSSNXWRKBK4N60
Follow Grifols Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 EUR · IFRS
Revenue, last year €7.5B +4.3% vs prior year
Net income €402M +156.2% vs prior year
EPS, diluted -
Operating cash flow €1B +16.1% vs prior year
Revenue by fiscal year
€5.3B
€4.9B
€6.1B
€6.6B
€7.2B
€7.5B
FY20 FY21 FY22 FY23 FY24 FY25

Source: ESEF annual reports · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income7 fiscal years
  • Revenue
  • Net income
€0€2B€4B€6B€8BFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25€7.5B€402M
FY24€7.2B€156.9M
FY23€6.6B€42.3M
FY22€6.1B€208.3M
FY21€4.9B€188.7M
FY20€5.3B€618.5M
FY19€5.1B€625.1M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
0%20%40%60%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2538%16.5%5.3%
FY2438.7%16.5%2.2%
FY2337.7%11.9%0.6%
FY2236.8%13.3%3.4%
FY2139.8%12.1%3.8%
FY2042.2%18.7%11.6%
FY1945.9%22.2%12.3%
Free cash flowOperating cash flow minus capital expenditure
−€500M€0€500M€1BFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25€782M
FY24€669.6M
FY23−€5.7M
FY22−€277.4M
FY21€349.6M
FY20€830.2M
FY19€258.6M
Returned to shareholdersDividends paid and shares bought back
  • Dividends
  • Buybacks
€0€100M€200M€300M€400MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearDividendsBuybacks
FY25€128M-
FY24€962K€0
FY23€0€0
FY22€592K€3.5M
FY21€258.9M€125.7M
FY20€113.2M-
FY19€238.7M-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Grifols
  • Healthcare median
−100%−75%−50%−25%0%25%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGrifolsHealthcare median
FY255.3%−30.6%
FY242.2%−47%
FY230.6%−58%
FY223.4%−80.4%
FY213.8%−71.9%
FY2011.6%−62.2%
FY1912.3%−46.3%